According to the Financial Associated Press on December 14 (Editor: Li Chen), market responses have been positive since the establishment of Share Buyback and Shareholding re-loans. As of the time of writing, this week (December 9 to December 14), 10 listed companies, including China Eastern Airlines Corporation, Joincare Pharmaceutical Group Industry, Yimikang Tech. Group.Co.,Ltd., Hangzhou Hikvision Digital Technology, CNSIG Inner Mongolia Chemical Industry, Beijing Bayi Space Lcd Technology Co.,Ltd., Zhejiang Jinfei Kaida Wheel, Northeast Pharmaceutical Group, Jiangzhong Pharmaceutical, and Henan Huanghe Whirlwind, have disclosed Share Buyback and Shareholding re-loan related situations, as shown in the chart below:

Among the listed companies utilizing special loans for Shareholding or Share Buyback plans, Hangzhou Hikvision Digital Technology plans to use self-owned funds and special loans for Share Buyback, with the maximum amount not exceeding 2.5 billion yuan.

The country's largest supplier of video surveillance products, Hangzhou Hikvision Digital Technology, announced on December 9 that it plans to repurchase shares worth 2 billion to -2.5 billion yuan for legal cancellation to reduce registered capital. The Share Buyback price Range does not exceed 40 yuan/share, with funding sourced from the company's self-owned funds and Share Buyback special loans. On December 13, Hangzhou Hikvision Digital Technology announced that it had recently received a notice from its controlling shareholder ZTE Corporation that ZTE Corporation had obtained a commitment letter for Shareholding special loans issued by Industrial And Commercial Bank Of China. The Hangzhou branch of Industrial And Commercial Bank Of China will provide ZTE Corporation with a loan not exceeding 0.12 billion yuan specifically for increasing the shareholding in Hangzhou Hikvision Digital Technology through centralized bidding, with a loan term not exceeding 3 years.

In addition, several listed companies such as China Eastern Airlines Corporation, Joincare Pharmaceutical Group Industry, Zhejiang Jinfei Kaida Wheel, and Northeast Pharmaceutical Group have also successively disclosed support for Share Buyback and Shareholding loan funds this week.

China Eastern Airlines Corporation, one of the three major state-owned backbone air transportation groups in China, announced on December 13 that it applied for a Share Buyback loan from the Shanghai branch of Bank Of Communications. This bank recently issued a commitment letter, promising to provide loans for this Share Buyback, with a loan amount of 0.45 billion yuan, specifically for the company's Share Buyback in the A-share market. Based on this, the funding source for this Share Buyback has changed from 'the company's self-owned funds' to 'the company's self-owned funds and borrowings from Financial Institutions.'

Joincare Pharmaceutical Group Industry, which is mainly engaged in the research and development of pharmaceutical products and health products, announced on December 11 that it has recently obtained a loan commitment letter from Industrial Bank, with a loan amount not exceeding 0.238 billion yuan, and not exceeding 90% of the maximum Share Buyback amount, with a loan term not exceeding 36 months, specifically for the purpose of repurchasing the listed company’s stocks. Joincare Pharmaceutical Group Industry previously announced on September 2 that it plans to repurchase shares through centralized bidding, with an amount no less than 0.3 billion yuan and not exceeding 0.5 billion yuan, to reduce the company's registered capital.

Zhejiang Jinfei Kaida Wheel, whose main business is in the research and development of aluminum alloy wheels such as turbine, motorcycle wheel, and electric wheel, announced on December 11 that its controlling shareholder Jinfei Holdings plans to increase shares in the company, with an amount ranging from 50 million to -0.1 billion yuan. China Construction Bank Corporation's Jinhua branch issued on December 10 a loan commitment letter to Jinfei Holdings, promising to provide a special Shareholding loan not exceeding 90 million yuan, with a loan term of 3 years.

Northeast Pharmaceutical Group, which mainly operates in Chemical Pharmaceuticals, announced on December 10 that its controlling shareholder, China Fangda Group, and its concerted action party, Jiangxi Fangda Steel Group Co., Ltd. (referred to as "Fangda Steel"), plan to increase their shareholding in the company within six months from the announcement date, with a planned increase of not less than 75 million yuan and not exceeding 150 million yuan. Fangda Steel will implement the shareholding plan based on a reasonable judgment of the company's stock price and according to the fluctuations in the company's stock price and the overall trend in the Capital Markets.